Terms: = Leukemia AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
45 results:
1. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
Ozga M; Nicolet D; Mrózek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ; Orwick S; Jurinovic V; Rothenberg-Thurley M; Dufour A; Schneider S; Sauerland MC; Görlich D; Krug U; Berdel WE; Woermann BJ; Hiddemann W; Braess J; Subklewe M; Spiekermann K; Carroll AJ; Blum WG; Powell BL; Kolitz JE; Moore JO; Mayer RJ; Larson RA; Uy GL; Stock W; Metzeler KH; Grimes HL; Byrd JC; Salomonis N; Herold T; Mims AS; Eisfeld AK
Leukemia; 2024 Jan; 38(1):45-57. PubMed ID: 38017103
[TBL] [Abstract] [Full Text] [Related]
2. Mechanism of Action of Decitabine in the Treatment of Acute Myeloid leukemia by Regulating LINC00599.
Du F; Jin T; Wang L
Anal Cell Pathol (Amst); 2023; 2023():2951519. PubMed ID: 36874552
[TBL] [Abstract] [Full Text] [Related]
3. Integration of CD34
Li XP; Zhang WN; Mao JY; Zhao BT; Jiang L; Gao Y
J Transl Med; 2022 Aug; 20(1):359. PubMed ID: 35962395
[TBL] [Abstract] [Full Text] [Related]
4. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.
Estruch M; Reckzeh K; Vittori C; Centio A; Ali M; Engelhard S; Zhao L; Won KJ; Liu P; Porse BT; Theilgaard-Mönch K
Leukemia; 2021 Jul; 35(7):2030-2042. PubMed ID: 33299144
[TBL] [Abstract] [Full Text] [Related]
5. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract] [Full Text] [Related]
7. [Primary plasma cell leukemia. Report of five cases].
Mendoza MG; Valladares X; Roa M; Reyes M; Osorio R; Undurraga MS; Legües ME; Cabrera ME; Peña C
Rev Med Chil; 2019; 147(1):18-23. PubMed ID: 30848760
[TBL] [Abstract] [Full Text] [Related]
8. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
Wu J; Lu AD; Zhang LP; Zuo YX; Jia YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):52-57. PubMed ID: 30704229
[No Abstract] [Full Text] [Related]
9. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on clinical outcome of Adult Acute Myeloid leukemia Patients.
Kandeel EZ; El Sayed G; Elsharkawy N; Eldin DN; Nassar HR; Ibrahiem D; Amin R; Hanafi M; Khalil M; Kamel A
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):541-547. PubMed ID: 29907544
[TBL] [Abstract] [Full Text] [Related]
10. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.
Naumann N; Jawhar M; Schwaab J; Kluger S; Lübke J; Metzgeroth G; Popp HD; Khaled N; Horny HP; Sotlar K; Valent P; Haferlach C; Göhring G; Schlegelberger B; Meggendorfer M; Hofmann WK; Cross NCP; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2018 May; 57(5):252-259. PubMed ID: 29341334
[TBL] [Abstract] [Full Text] [Related]
11. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract] [Full Text] [Related]
12.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract] [Full Text] [Related]
13. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid leukemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?
Yoon JH; Kim HJ; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2017 Apr; 23(4):588-597. PubMed ID: 28089879
[TBL] [Abstract] [Full Text] [Related]
15. clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.
Gao N; Yu WZ; Guo NJ; Wang XX; Sun JR
Leuk Lymphoma; 2017 Jun; 58(6):1394-1402. PubMed ID: 27736291
[TBL] [Abstract] [Full Text] [Related]
16. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed kit activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract] [Full Text] [Related]
17. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract] [Full Text] [Related]
18. Significance of kit exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.
Jang W; Yoon JH; Park J; Lee GD; Kim J; Kwon A; Choi H; Han K; Nahm CH; Kim HJ; Min WS; Kim M; Kim Y
Blood Cancer J; 2016 Jan; 6(1):e387. PubMed ID: 26771813
[TBL] [Abstract] [Full Text] [Related]
19. Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.
Schneider T; Flörcken A; Singh A; Türkmen S; Burmeister T; Anagnostopoulos I; Pezzutto A; Dörken B; Westermann J
Ann Hematol; 2015 Aug; 94(8):1337-45. PubMed ID: 25994787
[TBL] [Abstract] [Full Text] [Related]
20. Long non-coding RNA HOTAIR modulates c-kit expression through sponging miR-193a in acute myeloid leukemia.
Xing CY; Hu XQ; Xie FY; Yu ZJ; Li HY; Bin-Zhou ; Wu JB; Tang LY; Gao SM
FEBS Lett; 2015 Jul; 589(15):1981-7. PubMed ID: 25979172
[TBL] [Abstract] [Full Text] [Related]
[Next]
